Document is current

Article History

Received: 15 May 2025

Accepted: 28 July 2025

First Online: 11 August 2025

Declarations

:

: Yukari Okubo: Received research funding from AbbVie, Eisai, Maruho, Shiseido, Sun Pharma, and Torii Pharmaceutical; honoraria as a speaker, consultant, and advisory board member from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Kyowa Kirin, LEO Pharma, Eli Lilly, Maruho, Novartis, Pfizer, Sanofi, Sun Pharma, Taiho Pharma, and UCB; and honoraria as a speaker from Eisai, Jimro, Mitsubishi Tanabe Pharma, and Torii Pharmaceutical. Yayoi Tada: Research grants from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Eli Lilly, Jimro, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Meiji Seika Pharma, Sun Pharma, Taiho Pharma, Mitsubishi Tanabe Pharma, Torii Pharmaceutical, and UCB; honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Eisai, Janssen Pharma, Jimro, Kyowa Kirin, LEO Pharma, Maruho, Novartis, Sun Pharma, Taiho Pharma, Mitsubishi Tanabe Pharma, Torii Pharmaceutical, and UCB. Hidetoshi Takahashi: Served as paid speaker sponsored by AbbVie, Amgen, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sanofi, Sato Pharmaceutical, Sun Pharma, Taiho Pharma, Torii Pharmaceutical, and UCB. Masatoshi Abe: Served as paid speaker sponsored by AbbVie, Amgen, Eli Lilly, Kyowa Kirin, Maruho, Novartis, Sanofi, Torii Pharmaceutical, and UCB. Keiichi Yamanaka: Grants from Kaken Pharmaceutical, Maruho, Nihon Pharmaceutical, Nippon Kayaku, Otshuka Pharmaceutical, Sasaki Chemical, Sun Pharma, and Torii Pharmaceutical; speaker for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Eli Lilly, Janssen, Kaken Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nobelpharma, Novartis, Otshuka Pharmaceutical, Pfizer, Sanofi, Sun Pharma, Taiho Pharma, Torii Pharmaceutical, and UCB. Nicola Tilt, Nancy Cross, Delphine Deherder: Employees and shareholders of UCB. Mizuho Matano: Employee of UCB. Hidemi Nakagawa: Consulting fees and/or speaker’s fees from Japan Tobacco Inc., Maruho, Otsuka Pharmaceutical, Torii Pharmaceutical, and UCB.

: This study protocol was reviewed by a central institutional review board (IRB, approval number MOD01178825) and the IRB of each institution prior to implementation. Written informed consent was obtained from all patients. The study was carried out in accordance with the applicable regulatory and International Council for Harmonisation-Good Clinical Practice requirements, and the Helsinki Declaration of 1964, and its later amendments.